Gain Therapeutics (GANX) Cash from Financing Activities (2020 - 2026)

Gain Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $404321.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 83.13% year-over-year to $404321.0; the TTM figure through Mar 2026 stood at $26.5 million (up 70.07% YoY), while the FY2025 annual figure was $28.4 million, up 118.63% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $404321.0, down from $16.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $16.6 million in Q4 2025, with the low at -$145803.0 in Q1 2024.
• The 5-year median for Cash from Financing Activities is $808678.0 (2024), against an average of $3.2 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 121.69% in 2022, then surged 161115.26% in 2023.
• Gain Therapeutics' Cash from Financing Activities stood at -$21582.0 in 2022, then jumped by 44398.94% to $9.6 million in 2023, then plunged by 75.81% to $2.3 million in 2024, then surged by 615.62% to $16.6 million in 2025, then sank by 97.56% to $404321.0 in 2026.
• Business Quant data shows GANX's Cash from Financing Activities at $404321.0 in Q1 2026, $16.6 million in Q4 2025, and $7.0 million in Q3 2025.